Chemogenomics knowledge-based strategies in drug discovery

被引:31
作者
Jacoby, E [1 ]
Schuffenhauer, A [1 ]
Floersheim, P [1 ]
机构
[1] Novartis Pharma AG, Novartis Nervous Syst Res, CH-4002 Basel, Switzerland
关键词
D O I
10.1358/dnp.2003.16.2.829326
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the postgenomic age of drug discovery, targets can no longer be viewed as singular objects having no relationship to one another. All targets are now visible and the systematic exploration of selected target families appears to be a promising way to speed up and further industrialize target-based drug discovery. Chemogenomics refers to such systematic exploration of target families and aims to identify all possible ligands of all target families. Because biology works by applying prior knowledge to an unknown entity, chemogenomics approaches are expected to be especially effective within the previously well-explored target families, for which, in addition to the protein sequence and structure information, considerable knowledge of pharmacologically active structural classes and structure-activity relationships exists. For the new target families, chemical knowledge will have to be generated and beyond biological target validation, the emphasis is on chemistry to provide the molecules with which their novel biology and pharmacology can be studied. Using examples from the previously most successfully explored target families, the GPCR family in particular, we summarize herein our current chemogenomics knowledge-based strategies for drug discovery, which are founded on the high integration of chem and bioinformatics, thereby providing a molecular informatics frame for the exploration of the new target families. (C) 2003 Prous Science. All rights reserved.
引用
收藏
页码:93 / 102
页数:10
相关论文
共 48 条
[1]   Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14 [J].
Ames, RS ;
Sarau, HM ;
Chambers, JK ;
Willette, RN ;
Alyar, NV ;
Romanic, AM ;
Louden, CS ;
Foley, JJ ;
Sauermelch, CF ;
Coatney, RW ;
Ao, ZH ;
Disa, J ;
Holmes, SD ;
Stadel, JM ;
Martin, JD ;
Liu, WS ;
Glover, GI ;
Wilson, S ;
McNulty, DE ;
Ellis, CE ;
Elshourbagy, NA ;
Shabon, U ;
Trill, JJ ;
Hay, DWP ;
Ohlstein, EH ;
Bergsma, DJ ;
Douglas, SA .
NATURE, 1999, 401 (6750) :282-286
[2]  
[Anonymous], EUR J BIOCH
[3]   Gene Ontology: tool for the unification of biology [J].
Ashburner, M ;
Ball, CA ;
Blake, JA ;
Botstein, D ;
Butler, H ;
Cherry, JM ;
Davis, AP ;
Dolinski, K ;
Dwight, SS ;
Eppig, JT ;
Harris, MA ;
Hill, DP ;
Issel-Tarver, L ;
Kasarskis, A ;
Lewis, S ;
Matese, JC ;
Richardson, JE ;
Ringwald, M ;
Rubin, GM ;
Sherlock, G .
NATURE GENETICS, 2000, 25 (01) :25-29
[4]  
Barrett A.J., 1994, EUR J BIOCHEM, V223, P1, DOI [10.1111/j.1432-1033.1994.tb18960.x, DOI 10.1111/J.1432-1033.1994.TB18960.X]
[5]   Novel inhibitors of DNA gyrase: 3D structure based biased needle screening, hit validation by biophysical methods, and 3D guided optimization. A promising alternative to random screening [J].
Boehm, HJ ;
Boehringer, M ;
Bur, D ;
Gmuender, H ;
Huber, W ;
Klaus, W ;
Kostrewa, D ;
Kuehne, H ;
Luebbers, T ;
Meunier-Keller, N .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (14) :2664-2674
[6]   Chemogenomic approaches to drug discovery - Commentary [J].
Caron, PR ;
Mullican, MD ;
Mashal, RD ;
Wilson, KP ;
Su, MS ;
Murcko, MA .
CURRENT OPINION IN CHEMICAL BIOLOGY, 2001, 5 (04) :464-470
[7]   Sequence and structure classification of kinases [J].
Cheek, S ;
Zhang, H ;
Grishin, NV .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 320 (04) :855-881
[8]  
CROSSLEY R, 2002, GOR, V4, P20
[9]  
*CURR DRUGS LTD, IDDB INV DRUGS DAT
[10]  
*DERW INF LTD, DERW WORLD DRUG IND